Ph3 Vusolimogene Oderparepvec + Nivo vs Physician's Choice in adv Melanoma
Phase III Clinical Trial
A Randomized Controlled Multicenter Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physicians Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen [IGNYTE-3] (RP1-104)